ASCO 2024 | HCRN MEL17-309: Phase II study of adjuvant nivolumab with ipilimumab in high-risk uveal melanoma

Suthee Rapisuwon, MD, Georgetown University, Washington, DC, discusses a prospective multi-center phase II study of adjuvant nivolumab/ipilimumab in high-risk uveal melanoma patients. With a median follow-up of 36 months, the 3-year distant metastatic-free survival (DMFS) rate was significantly improved at 70.4% compared to 43.4% in the control cohort. Although treatment-related adverse events were common, this regimen shows promise as adjuvant therapy for high-risk uveal melanoma, warranting further investigation. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.